DE69319710T2 - Zusammensetzungen, die Cholesterin Ester von ungesättigten Fettsäure enthalten - Google Patents

Zusammensetzungen, die Cholesterin Ester von ungesättigten Fettsäure enthalten

Info

Publication number
DE69319710T2
DE69319710T2 DE69319710T DE69319710T DE69319710T2 DE 69319710 T2 DE69319710 T2 DE 69319710T2 DE 69319710 T DE69319710 T DE 69319710T DE 69319710 T DE69319710 T DE 69319710T DE 69319710 T2 DE69319710 T2 DE 69319710T2
Authority
DE
Germany
Prior art keywords
fatty acids
compositions containing
unsaturated fatty
cholesterol esters
containing cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69319710T
Other languages
English (en)
Other versions
DE69319710D1 (de
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Publication of DE69319710D1 publication Critical patent/DE69319710D1/de
Application granted granted Critical
Publication of DE69319710T2 publication Critical patent/DE69319710T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69319710T 1993-01-06 1993-12-29 Zusammensetzungen, die Cholesterin Ester von ungesättigten Fettsäure enthalten Expired - Fee Related DE69319710T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939300125A GB9300125D0 (en) 1993-01-06 1993-01-06 Compositions containing esters of unsaturated fatty acids

Publications (2)

Publication Number Publication Date
DE69319710D1 DE69319710D1 (de) 1998-08-20
DE69319710T2 true DE69319710T2 (de) 1999-03-11

Family

ID=10728334

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69319710T Expired - Fee Related DE69319710T2 (de) 1993-01-06 1993-12-29 Zusammensetzungen, die Cholesterin Ester von ungesättigten Fettsäure enthalten

Country Status (17)

Country Link
US (1) US5604216A (de)
EP (1) EP0606012B1 (de)
JP (1) JPH06234644A (de)
KR (1) KR940018088A (de)
CN (1) CN1096197A (de)
AT (1) ATE168267T1 (de)
AU (1) AU673555B2 (de)
CA (1) CA2112824A1 (de)
DE (1) DE69319710T2 (de)
DK (1) DK0606012T3 (de)
ES (1) ES2119871T3 (de)
GB (1) GB9300125D0 (de)
MY (1) MY110765A (de)
NO (1) NO940035D0 (de)
NZ (1) NZ250583A (de)
RU (1) RU2142468C1 (de)
ZA (1) ZA9425B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
NZ333817A (en) * 1998-08-25 2000-09-29 Mcneil Ppc Inc Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
US5892068A (en) * 1998-08-25 1999-04-06 Mcneil-Ppc, Inc. Preparation of sterol and stanol-esters
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
WO2000062772A1 (fr) * 1999-04-15 2000-10-26 Kaneka Corporation Agonistes du recepteur sensible a l'activateur du type peroxysome
WO2001015552A1 (en) * 1999-08-30 2001-03-08 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
US6998501B1 (en) * 1999-08-30 2006-02-14 Ocean Nutrition Canada Limited Nutritional supplement for lowering serum triglyceride and cholesterol levels
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
EP1121928B1 (de) * 2000-01-31 2008-01-23 Härting S.A. Zusammensetzungen enthaltend Phytosterol- und Policosanolester von Fettsäuren zur Herabsetzung des Cholesterol- und Triglyceridspiegels
KR20010091499A (ko) * 2000-03-16 2001-10-23 김용범 레이저 그래픽 디스플레이 장치
AU2002305099A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty alcohol drug conjugates
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
WO2004068970A2 (en) * 2003-01-31 2004-08-19 The Procter & Gamble Company Means for improving the appearance of mammalian keratinous tissue
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
CA2529735C (en) * 2003-06-20 2012-07-10 Mochida Pharmaceutical Co., Ltd. Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US20060141046A1 (en) * 2004-05-06 2006-06-29 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
WO2005107710A2 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
ES2617577T3 (es) * 2005-07-08 2017-06-19 Dsm Ip Assets B.V. Ácidos grasos poliinsaturados para el tratamiento de la demencia y afecciones relacionadas con la pre-demencia
US20080110624A1 (en) * 2005-07-15 2008-05-15 Halliburton Energy Services, Inc. Methods for controlling water and particulate production in subterranean wells
ITMI20052377A1 (it) * 2005-12-13 2007-06-14 Anna Petroni Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP3187182B1 (de) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
WO2010093634A1 (en) 2009-02-10 2010-08-19 Amarin Pharma, Inc. Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101343249B1 (ko) 2009-04-29 2013-12-19 아마린 파마, 인크. 안정한 제약 조성물 및 그의 사용 방법
CN108096237A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
EP2495242B1 (de) * 2009-10-29 2016-05-04 Industry-Academic Cooperation Foundation Yonsei University Neuer gefässundichtigkeitshemmer
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
KR20150036252A (ko) 2012-06-29 2015-04-07 애머린 파마슈티칼스 아일랜드 리미티드 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법
EP2906199B1 (de) * 2012-10-11 2018-01-03 Anaplasi Pharmaceuticals LLC Verfahren und zusammensetzungen zur behandlung von schuppenflechte
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6224203B2 (ja) * 2016-12-08 2017-11-01 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するための組成物
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP6491293B2 (ja) * 2017-10-04 2019-03-27 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN111991386A (zh) 2018-09-24 2020-11-27 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
JP6728425B2 (ja) * 2019-02-28 2020-07-22 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するためのクリーム、ローション、又はゲルの組成物

Also Published As

Publication number Publication date
MY110765A (en) 1999-03-31
CA2112824A1 (en) 1994-07-07
AU673555B2 (en) 1996-11-14
NO940035D0 (no) 1994-01-05
DE69319710D1 (de) 1998-08-20
NO940035L (de) 1994-07-07
EP0606012B1 (de) 1998-07-15
DK0606012T3 (da) 1999-04-19
ATE168267T1 (de) 1998-08-15
JPH06234644A (ja) 1994-08-23
ES2119871T3 (es) 1998-10-16
AU5276393A (en) 1994-07-14
GB9300125D0 (en) 1993-03-03
RU2142468C1 (ru) 1999-12-10
KR940018088A (ko) 1994-08-16
ZA9425B (en) 1994-08-19
NZ250583A (en) 1997-08-22
CN1096197A (zh) 1994-12-14
US5604216A (en) 1997-02-18
EP0606012A1 (de) 1994-07-13

Similar Documents

Publication Publication Date Title
DE69319710T2 (de) Zusammensetzungen, die Cholesterin Ester von ungesättigten Fettsäure enthalten
RU94000061A (ru) Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция
ATE106867T1 (de) 13-trans-retinsäureester.
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
ATE208608T1 (de) Kosmetische oder dermatologische zusammensetzung, die ein alpha-hydroxysäure, salicylsäure und ein retinoid enthalten
AU7053494A (en) Method of treating coronary vascular disease using docosahexaenoic acid
CA2144312A1 (en) Unsaturated aliphatic dicarboxylic acids
DE69312579D1 (de) Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
DE69302883T2 (de) L-Carnitin- und Alkanoyl-L-Carnitin-Ester mit Glykolsäure oder ihre Ester und diese enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen
DE69315927D1 (de) Kosmetische Zusammensetzung, die einen Lipidstoff und eine Hydroxy - oder Ketofettsäure enthält
DE59504267D1 (de) Härten von ungesättigten fetten, fettsäuren oder fettsäureestern
DE69302098T2 (de) Zusammensetzungen von hexitan-fettsäureestern
FI883310A0 (fi) Rengoeringsmedelkomposition och dess anvaendning.
DE3760876D1 (en) Cyclohexane-, cyclohexene- and cyclohexadiene, bicycloû2.2.1¨heptane and bicyclo û2.2.1¨heptenecarboxylic acid esters, and also perfume compositions and perfumed products which contain one or more of said compounds as perfume component
DE3784738D1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
ATE113291T1 (de) Polyaromatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.
ES2191671T3 (es) Esteres de 1,4-dihidropiridina 4-fenil-3-sustituidos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee